Acetazolamide for Treatment Resistant Schizophrenia
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-55
SponsorVishwajit Nimgaonkar, MD PhD
About this trial
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
Eligibility criteria
Qualifiers
Written informed consent.
Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).
PANSS total score > 60 and Score > 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.
Stable dose of antipsychotic drug (APD) for > 1 month, continued throughout the study.
Disqualifiers
Substance abuse in the past month/dependence past 6 months with the exception of methadone prescribed for opiate withdrawal.
History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.
Pregnancy.
Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.
Trial design
Treatments tested in this trial
- Acetazolamide
- Placebo
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Vishwajit Nimgaonkar, MD PhD
Lead sponsor
University of Pittsburgh
Sponsor institution
Stanley Medical Research Institute
Collaborator
Source ClinicalTrials.gov